CommentaryClinical Trials

Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

Science Translational Medicine  23 Mar 2011:
Vol. 3, Issue 75, pp. 75cm9
DOI: 10.1126/scitranslmed.3001712

You are currently viewing the abstract.

View Full Text

Abstract

Enrollment of patients in a clinical trial is difficult as a result of a host of well-documented barriers. In the field of oncology, molecularly targeted treatments have demonstrated considerable therapeutic promise. At the same time, clinical testing of these targeted agents has introduced new complexities in the decision-making process by patients or providers on whether to participate in clinical trials. Explored in this Commentary are challenges of and potential solutions for the clinical testing of modern cancer therapies.

Footnotes

  • Citation: R. L. Schilsky, Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. Sci. Transl. Med. 3, 75cm9 (2011).

View Full Text